SOPHiA GENETICS (SOPH) Competitors $3.14 +0.13 (+4.32%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$3.12 -0.02 (-0.64%) As of 08/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SOPH vs. UPB, ORIC, ATAI, PHAR, CRMD, NUVB, DNA, IMTX, SION, and CRONShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Upstream Bio (UPB), Oric Pharmaceuticals (ORIC), atai Life Sciences (ATAI), Pharming Group (PHAR), CorMedix (CRMD), Nuvation Bio (NUVB), Ginkgo Bioworks (DNA), Immatics (IMTX), Sionna Therapeutics (SION), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. Its Competitors Upstream Bio Oric Pharmaceuticals atai Life Sciences Pharming Group CorMedix Nuvation Bio Ginkgo Bioworks Immatics Sionna Therapeutics Cronos Group Upstream Bio (NASDAQ:UPB) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Which has better valuation & earnings, UPB or SOPH? SOPHiA GENETICS has higher revenue and earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M398.07-$62.81MN/AN/ASOPHiA GENETICS$65.17M3.26-$62.49M-$0.44-7.14 Do institutionals & insiders believe in UPB or SOPH? 31.6% of SOPHiA GENETICS shares are held by institutional investors. 13.6% of Upstream Bio shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer UPB or SOPH? In the previous week, Upstream Bio had 8 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 12 mentions for Upstream Bio and 4 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.83 beat Upstream Bio's score of -0.23 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SOPHiA GENETICS 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is UPB or SOPH more profitable? SOPHiA GENETICS has a net margin of -40.99% compared to Upstream Bio's net margin of -3,836.58%. SOPHiA GENETICS's return on equity of -30.69% beat Upstream Bio's return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-3,836.58% -35.90% -26.26% SOPHiA GENETICS -40.99%-30.69%-17.39% Do analysts rate UPB or SOPH? Upstream Bio presently has a consensus target price of $56.50, suggesting a potential upside of 222.86%. SOPHiA GENETICS has a consensus target price of $8.00, suggesting a potential upside of 154.78%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00SOPHiA GENETICS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySOPHiA GENETICS beats Upstream Bio on 7 of the 12 factors compared between the two stocks. Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.41M$1.96B$5.49B$9.69BDividend YieldN/AN/A4.64%4.14%P/E Ratio-7.1433.9530.4025.31Price / Sales3.269.73444.45101.55Price / CashN/A50.2637.7258.50Price / Book2.785.688.306.01Net Income-$62.49M-$62.35M$3.26B$265.10M7 Day Performance-0.32%-0.02%1.53%1.39%1 Month Performance-10.03%-2.54%3.73%2.43%1 Year Performance-7.37%24.76%41.02%24.74% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS2.0847 of 5 stars$3.14+4.3%$8.00+154.8%-1.6%$203.41M$65.17M-7.14520Gap UpUPBUpstream Bio1.755 of 5 stars$15.80+1.2%$56.50+257.7%N/A$847.85M$2.30M0.0038Earnings ReportORICOric Pharmaceuticals4.2045 of 5 stars$9.89+1.4%$18.57+87.8%+15.0%$843.25MN/A-5.2980News CoveragePositive NewsEarnings ReportATAIatai Life Sciences2.6713 of 5 stars$4.19-1.6%$11.25+168.4%+233.1%$836.41M$1.86M-4.5980PHARPharming Group2.7767 of 5 stars$12.16-0.7%$30.00+146.7%+48.3%$822.81M$297.20M-92.38280Gap DownCRMDCorMedix3.1701 of 5 stars$11.96-3.3%$17.14+43.3%+215.9%$815.19M$82.55M54.6330News CoveragePositive NewsEarnings ReportAnalyst RevisionNUVBNuvation Bio1.9589 of 5 stars$2.39+3.2%$7.17+200.5%-17.7%$811.52M$7.87M-1.0160Earnings ReportDNAGinkgo Bioworks0.8881 of 5 stars$13.80+1.5%$8.50-38.4%N/A$802.74M$227.04M-1.50640News CoverageEarnings ReportIMTXImmatics2.8035 of 5 stars$6.56-0.8%$14.67+123.6%-43.5%$797.37M$168.65M-38.59260News CoverageSIONSionna TherapeuticsN/A$17.76+3.7%$38.50+116.8%N/A$783.57MN/A0.0035News CoverageEarnings ReportGap UpCRONCronos Group1.4094 of 5 stars$2.04+0.7%N/A+18.5%$781.05M$117.61M15.66450Trending NewsEarnings ReportAnalyst Revision Related Companies and Tools Related Companies UPB Alternatives ORIC Alternatives ATAI Alternatives PHAR Alternatives CRMD Alternatives NUVB Alternatives DNA Alternatives IMTX Alternatives SION Alternatives CRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SOPH) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access